

BIOGRAPHICAL SKETCH

Provide the following information for the key personnel in the order listed for Form Page 2.
Follow the sample format on for each person. (See attached sample). **DO NOT EXCEED FOUR PAGES.**

NAME		POSITION TITLE	
Joseph R. Pisegna, M.D.		Associate Professor in Residence	
EDUCATION/TRAINING <i>(Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.)</i>			
INSTITUTION AND LOCATION	DEGREE <i>(if applicable)</i>	YEAR(s)	FIELD OF STUDY
University of Miami, Coral Gables, FL	B.A.	1982	Biology and Religion
University of Miami School of Medicine, Miami, FL	M.D.	1986	Medicine

A. Positions and Honors.**Positions and Employment**

1986 – 1987	Internship in Internal Medicine, University of Miami/Jackson Memorial Hospital, Miami, FL
1987 – 1989	Resident in Internal Medicine, University of Miami/Jackson Memorial Hospital, Miami, FL
1990 – 1996	Commander, United States Public Health Service, National Institutes of Diabetes, and Digestive and Kidney Diseases, National Institutes of Health.
1992 – 1995	Chief of the Clinical Research Unit and Attending Physician, Endoscopy Unit, Digestive Diseases Branch, National Institutes of Health.
1992 – 1996	Research Assistant Professor of Medicine, Georgetown Univ. School of Medicine, Georgetown, WA.
1996 – 2001	Assistant Professor of Medicine, UCLA School of Medicine, Los Angeles, CA.
1997 – Present	Research Associate, VA Career Development Program, West LA VAMC, Los Angeles, CA.
1998 – Present	Assistant Director, UCLA Affiliated Training Programs in Gastroenterology
1999 – Present	Chief, Division of Gastroenterology and Hepatology, VA Greater Los Angeles Health Care Center
2001 – Present	Associate Professor in Residence, Department of Medicine UCLA School of Medicine

Honors

1980	Golden Key National Honor Society
1980	Beta Beta Beta Biology Honor Society
1980	Delta Theta Mu Arts and Sciences Honor Society
1981	Honor Society of Phi Kappa Phi
1982 – 1986	University of Miami School of Medicine Board of Trustees Scholarship
1985	Bockus International Society of Gastroenterology Alpha Omega Alpha National Medical Honor Society
1996 – 1997	CURE: VA/UCLA Named New Investigator
1997 – Present	VA Career Development Award Level II

B. Selected peer-reviewed publications (in chronological order).

- Pisegna JR**, Norton JA, Slimak GG, Metz DC, Maton PN, Gardner JD, Jensen RT. Effects of curative gastrinoma resection on gastric secretory function and antiseecretory drug requirements in patients with Zollinger-Ellison Syndrome. *Gastroenterology* 1992;102:767-78.
- Helander HF, Rutgersson K, Helander KG, **Pisegna JR**, Gardner JD, Jensen RT, Maton PN. Stereologic investigations of human gastric mucosa; Oxynic mucosa from patients with Zollinger-Ellison Syndrome. *Scand J Gastroenterol* 1992;27:875-883.
- Wank SA, **Pisegna JR**, de Weerth A. Molecular cloning of the rat cholecystokinin type B receptor; structure, and functional expression. *Proc Natl Acad Sci USA* 1992;89:8691-8695.
- Pisegna JR**, deWeerth A, Huppi K, Wank SA. Molecular cloning of the human brain and gastric cholecystokinin receptor; structure, functional expression and chromosomal localization. *Biochem Biophys Res Comm* 1992;189:296-303.
- Pisegna JR**, Wank SA. Molecular cloning and functional expression of the pituitary adenylate cyclase-activating polypeptide type I receptor. *Proc Natl Acad Sci USA* 1993;90:6345-6349.
- Pisegna JR**, Doppman JL, Norton JA, Metz DC, Jensen RT. Prospective assessment of MR imaging compared to CT, US, and angio in localizing gastrinomas in patients with Zollinger-Ellison Syndrome. *Dig Dis Sci* 1993;38:1318-1328

7. de Weerth A, **Pisegna JR**, Wank SA. Molecular cloning, functional expression and chromosomal localization of the human cholecystokinin type A receptor. *Biochem Biophys Res Comm* 1993;194:811-818.
8. **Pisegna JR**, Slimak GG, Doppman JL, Strader DB, Metz DC, et al. An evaluation of human recombinant alpha interferon in patients with metastatic gastrinoma. *Gastroenterology* 1993;105:1179-1183.
9. de Weerth A, **Pisegna JR**, Wank SA Guinea pig gallbladder and pancreas possess identical CCK-A receptor subtypes: Receptor cloning and expression. *Am J Physiol* 1993;265:G1116-21.
10. Huppi K, Siwarski D, **Pisegna JR**, Wank SA. Chromosomal localization of the gastric and brain receptors for cholecystokinin (CCKAR and CCKBR) in human and mouse. *Genomics* 1995;25:727-729.
11. Zia F, Fagarasan M, Bitar K, Coy DH, **Pisegna JR**, Wank SA, Moody TW. PACAP receptors regulate the growth of non-small cell lung cancer cells. *Cancer Research* 1996;55:4886-4891.
12. **Pisegna JR**, Wank SA. Cloning and characterization of the signal transduction of four splice variants of the human pituitary adenylate cyclase activating polypeptide receptor: Evidence for dual coupling to adenylate cyclase and phospholipase C. *J Biol Chem* 1996;271:17267-17271.
13. **Pisegna JR**, Leyton J, Coelho T, Hida T, Jakolew S, Birrer S, Fridkin M, Gozes I, Moody TW. Differential activation of immediate-early gene expression by four splice variants of the human pituitary activating polypeptide receptor: evidence for an activation by PACAP hybrid and the phospholipase C inhibitor U73122. *Life Sci* 1997;61:631-639.
14. Pohl M, Poirot SS, **Pisegna JR**, Tarasova NI, Wank SA. The carboxy-terminus of the cholecystokinin B receptor (CCKBR), unlike that of the type A receptor (CCKAR), is essential for ligand-induced internalization. *J Biol Chem* 1997;272:18179-18184.
15. Harmar AJ, Arimura A, Gozes I, Journot L, Laburthe M, **Pisegna JR**, et al. International union of pharmacology. XVIII. Nomenclature of receptors for vasoactive intestinal polypeptide and pituitary adenylate cyclase activating polypeptide. *Pharmacol Rev* 1998;50:265-270.
16. Lew EA, Lewin KL, Zarchy T, **Pisegna JR**. Adenocarcinoma of the colon with neuroendocrine features and secretory diarrhea. *Am J Gastroenterol* 1999;94:1692-4.
17. **Pisegna JR**, Lew EA, Martin P, McKend WM, Ohning G, Walsh JH, Paul J. Inhibition of pentagastrin-induced gastric acid secretion by intravenous pantoprazole: A dose response study. *Am J Gastroenterol* 1999;94:2874-2880.
18. Zeng N, Kang T, Wong H, Walsh JH, Sachs GA, **Pisegna JR**. PACAP type I receptor activation regulates ECL cells and gastric acid secretion *J Clin Invest* 1999;104:1383-1391.
19. Leyton J, Gozes Y, **Pisegna JR**, Coy D, Purdom S, Casibang M, Zia F, Moody TW. PACAP (6-38) is a PACAP receptor antagonist for breast cancer cells. *Breast Cancer Research and Treatment* 1999;56:177-186.
20. Lew EA, **Pisegna JR**, Starr JA, Soffer EF, Forsmark C, Modlin IM, Walsh JH, Beg M, Bochenek W, Metz DC. Intravenous pantoprazole is a novel proton pump inhibitor that rapidly and effectively controls gastric acid hypersecretion in patients with Zollinger Ellison Syndrome. *Gastroenterology* 2000;118:696-704.
21. Sarosiek J, Jensen RT, Maton PM, Peura DA, Harlow D, Tianqing F, McCallum RW, **Pisegna JR**. Salivary and gastric epidermal growth factor in patients with Zollinger-Ellison Syndrome: Its protective potential. *Am J Gastroenterol* 2000;95:1158-1166.
22. Metz DC, Pratha V, Martin P, Paul J, Maton PN, **Pisegna JR**. Oral and intravenous dosage forms of pantoprazole are equivalent in their ability to suppress gastric acid secretion in patients with gastroesophageal reflux disease. *Am J Gastroenterol* 2000;95:626-633.
23. Lyu R-M, Germano PM, Choi JK, Le S, **Pisegna JR**. The crucial amino acids within the carboxyl terminus of the PACAP receptor that are involved with signal transduction and receptor internalization: Identification of a conserved amino acid motif for members of the class II receptor family. *J Biol Chem* 2000;275:36134-36142.
24. Germano PM, Stalter J, Le SV, Wu M, Yamaguchi DJ, Scott D, **Pisegna JR**. Characterization of the pharmacology, signal transduction and internalization of a fluorescent PACAP ligand, fluor-PACAP, on NIH 3T3 cells expressing PAC1. *Peptides* 2001;22:861-866.
25. Metz DC, Forsmark C, Lew EA, Starr JA, Soffer EF, Bochenek W, **Pisegna JR**. Replacement of oral proton pump inhibitors with intravenous pantoprazole to effectively control gastric acid hypersecretion in patients with Zollinger-Ellison syndrome. *Am J Gastroenterol* 2001;96:3274-80.
26. Metz DC, Ferron GM, Paul J, Turner MB, Soffer E, **Pisegna JR**, Bochenek WJ. Proton pump activation in stimulated parietal cells is regulated by gastric acid secretory capacity: A human study. *J Clin Pharmacol* 2002;42:512-9.
27. Miampamba M, Germano PM, Arli S, Wong HH, Scott D, Tache Y, **Pisegna JR**. Expression of pituitary adenylate cyclase-activating polypeptide and PACAP type 1 receptor in the rat gastric and colonic myenteric neurons. *Regul Pept* 2002;105:145-54.

C. Research Support

Ongoing Research Support

1 R21 DK063607-01 (co-PI)

11/1/02 – 10/31/04

NIH
Models of insulin production in enteroendocrine cells
This grant is focused on the elucidation of neuroendocrine cell regulation in the GI tract using a model system using an insulin gene promoter.

Role: Co-Investigator

VA Merit Review Pisegna (PI)

10/1/00 – 9/30/05

PACAP Regulation of Gastric Acid Secretion

This grant investigates the localization and function of PACAP and the PACAP receptor in the gastrointestinal tract.

Role: PI

Completed Research Support

Wyeth Ayerst Protocol 307 Pisegna (PI)

8/1/02 – 7/30/03

Long Term Maintenance of Zollinger Ellison Syndrome with Pantoprazole

This clinical research grant is focused on the regulation of gastric acid secretion by the novel proton pump inhibitor, pantoprazole, in patients with the neuroendocrine tumor, gastrinoma.

Role: PI

UCLA Faculty Senate Award Pisegna (PI)

10/1/01 – 9/30/03

Regulation of Immune Function by PACAP

This grant is focused on investigations elucidating the regulation of lymphocyte function by PACAP

Role: PI